Nephropathy

Nephrology·MeSH: Kidney Diseases

Prevalence

25.0 / 100K

Incidence

2.5 / 100K/yr

46 drugs in development·28 companies·2 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
Bumetanide for Injection	CHINA PHARMA HOLDINGS, INC. (CPHI)
FILSPARI®	Travere Therapeutics, Inc. (TVTX)
losartan	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(11)

Drug	Company
alxn1920	ALEXION PHARMACEUTICALS, INC. (ALXN)
atrasentan	CHINOOK THERAPEUTICS, INC. (KDNY)
Belimumab	Crinetics Pharmaceuticals, Inc. (CRNX)
Belimumab	ENANTA PHARMACEUTICALS INC (ENTA)
bion-1301	NOVARTIS AG (NVSEF)
bion-1301	Novartis AG (NVS)
Irbesartan	Travere Therapeutics, Inc. (TVTX)
lnp023	Novartis AG (NVS)
oms721	OMEROS CORP (OMER)
ravulizumab	Hepion Pharmaceuticals, Inc. (CTRVP)
zigakibart	Novartis AG (NVS)

Phase 2(15)

Drug	Company
adx-097	Q32 Bio Inc. (QTTB)
AKB-097	Akebia Therapeutics, Inc. (AKBA)
ALXN1920	ARS Pharmaceuticals, Inc. (SPRY)
Atacicept	Vera Therapeutics, Inc. (VERA)
atrasentan	Novartis AG (NVS)
blisibimod	ANTHERA PHARMACEUTICALS INC (ANTH)
budoprutug	Climb Bio, Inc. (CLYM)
Felzartamab	BIOGEN INC. (BIIB)
GKT137831	Calliditas Therapeutics AB (CALT)
jade101	Jade Biosciences, Inc. (JBIO)
NK Cells	Filana Therapeutics Inc. (FLNA)
sparsentan	Travere Therapeutics, Inc. (TVTX)
xh-s003	INFINITY PHARMACEUTICALS, INC. (INFI)
zaltenibart	OMEROS CORP (OMER)
zigakibart	Novartis AG (NVS)

Phase 1(5)

Drug	Company
ARO-CFB	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
BHV-1400	Biohaven Ltd. (BHVN)
Dual-Target Antigen-Selected CAR-NK	Filana Therapeutics Inc. (FLNA)
EB-SELECT Single-Target CAR-NK Cells	Filana Therapeutics Inc. (FLNA)
povetacicept	VERTEX PHARMACEUTICALS INC / MA (VRTX)

Preclinical(1)

Drug	Company
labp-69	Landos Biopharma, Inc. (LABP)

Phase 1/Phase 2(3)

Drug	Company
bion-1301	CHINOOK THERAPEUTICS, INC. (KDNY)
bion-1301 multiple doses	Novartis AG (NVS)
bion-1301 single dose	Novartis AG (NVS)

Phase 2/Phase 3(1)

Drug	Company
Tacrolimus	BeOne Medicines Ltd. (ONC)

Phase 4(7)

Drug	Company
atrasentan	NOVARTIS AG (NVSEF)
Dapagliflozin	Travere Therapeutics, Inc. (TVTX)
Efgartigimod IV	ARGENX SE (ARGX)
efgartigimod iv or efgartigimod ph20 sc	ARGENX SE (ARGX)
No sparsentan	Travere Therapeutics, Inc. (TVTX)
ravulizumab	ALEXION PHARMACEUTICALS, INC. (ALXN)
TARPEYO®	Calliditas Therapeutics AB (CALT)

BioSniper tracks 46 drugs in development for Nephropathy across 28 companies.

There are 2 clinical trials targeting Nephropathy tracked by BioSniper.

The estimated prevalence of Nephropathy is approximately 25.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.